Avoid This Biotech Stock

Editor's note: This article is a stock pitch made by a member on CAPS, The Motley Fool's free investing community. The pitch is published UNEDITED and is the opinion of the CAPS member whose pitch it is, in this case: zzlangerhans.

Each week, Motley Fool editors cull a top stock idea from the pitches made on CAPS, the Motley Fool's 180,000-member free investing community. Want your idea considered for this series? Make a compelling pitch on CAPS with a minimum length of 400 words. Want to follow our weekly picks? Subscribe to our RSS feed or follow us on Twitter.

Company Antares Pharma (AMEX: AIS  )
Submitted By zzlangerhans
Member Rating 99.39
Submitted On 11/16/2011
Stock Price at Underperform Recommendation $2.58
Antares Pharma profile
Star Rating (out of 5) ***
Headquarters Ewing, N.J.
Industry Biotechnology
Market Cap $271 million
Industry Peers Jazz Pharmaceuticals (Nasdaq: JAZZ  )
Novavax (Nasdaq: NVAX  )
Columbia Laboratories (Nasdaq: CBRX  )

Sources: S&P Capital IQ, Yahoo! Finance, and Motley Fool CAPS

This Week's Pitch:

A large float allows Antares to hide a generous market cap of 270M behind a puny share price of 2.6. Antares' share price has nearly doubled this year, likely due to enthusiasm over potential FDA approval of Anturol for overactive bladder on 12/8/11. Antares also has some stake in [BioSante Pharmaceuticals' (Nasdaq: BPAX  ) ] Libigel, so when Biosante goes up Antares will usually do the same.

I'm not too excited about Anturol. Approved or not, this is a transdermal reformulation of a medication that has been generic in the oral form for years. Of course, the company has a million and one reasons why Anturol is better than generic oral oxybutynin but I'm not convinced that urologists will buy in. In July the company partnered Anturol with [Watson Pharmaceuticals (NYSE: WPI  ) ] for undisclosed compensation, which usually means low compensation. In Q3 total development revenue was 1M, indicating that their compensation from Watson was less than 1M. Even if they are amortizing an upfront payment over several quarters, that doesn't amount to much. I'm guessing the deal was heavily backloaded, likely because Watson sees a high risk of this product not taking off commercially.

Libigel is more of a wild card. Antares has international marketing rights if Libigel is approved, and the share price could certainly pop in the short-term with positive phase III efficacy data for Libigel before the end of 2011. Long-term I don't think the commercial prospects for Libigel are good but I do have a green thumb on Biosante with the expectation of positive data. So my red thumb on Antares is somewhat contradictory in that respect. I see the upward momentum this week being somewhat excessive, and I'd like to escape the red thumb with a positive score before the Anturol PDUFA and Libigel data. If not, I might be in this for a while.

Follow this!
Want to follow our weekly picks? Subscribe to our RSS feed or follow us on Twitter.

The Motley Fool is investors writing for investors. Dan Dzombak did not have a position in any of the companies mentioned in this article. Pitches must be compelling, made in the past 30 days, and be at least 400 words. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (11) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 22, 2011, at 4:02 PM, erikshun wrote:

    wow, great analysis on libigel there, champ.

    "Long-term I don't think the commercial prospects for Libigel are good" and then you go on to provide no basis or reasoning for that statement.

    there is a well-over $1B+ potential there for this product. there are thousands of non-fda-approved off-label prescriptions for FSDD every month by doctors who would prefer an fda-approved product.

    AIS will probably be near 4 in early 2012, but you have an article titled 'Avoid this Biotech Stock'.

    this really reflects poorly on the ol' Fool......

  • Report this Comment On November 22, 2011, at 4:03 PM, techperson wrote:

    Wow, I never saw someone short a stock into BOTH FDA approval of one drug AND positive Phase III data on another drug. Good luck with that!

    "Long-term I don't think the commercial prospects for Libigel are good." I'm sure you realize you are in a tiny minority, so it would be nice to know your reasons - if any,

  • Report this Comment On November 22, 2011, at 4:21 PM, yazzbro wrote:

    Sorry bro, have to disagree with you there. Libigel would be a first in class medication for what might prove to be a multi-billion dollar unmet segment. Take a look at Viagra. If Libigel is a tenth of what Viagra's sales are then Libigel will be a huge huge success. Realize this, Micro-cap pharm stocks like these are completely Hype driven. Holding these stocks for the long haul usually never proves to be successful. However, since these stocks are hype driven, the hype of good topline results from Libigel and the FDA approval of Anturol should pop this stock well into the double digits. That is when you sell it. Holding it long term then becomes risky. You sell on good news. Anyway, best of luck with your short selling of Antares. But be prepared to be squeezed out next month.

  • Report this Comment On November 22, 2011, at 4:26 PM, yazzbro wrote:

    erikshun, $4?? That is a very low conservative estimate. I say $4 if only one of the next months catalyst come to fruition. If both catalyst pop next month, start listening for buyout talk which will send this stock well over $10. This could be a 5 bagger for sure,(assuming good news on both fronts.) But even good news on one will be send this stock upwards of $4 or $5.

  • Report this Comment On November 22, 2011, at 4:32 PM, bioguru101111 wrote:

    You're the most ignorant short I've ever seen. At least bring some good reasoning to support your truly foolish comments. AIS will double in 1Q'12 and with good safety results will go north of 7 and be double digits by launch of Libigel.

  • Report this Comment On November 22, 2011, at 5:29 PM, noamps wrote:

    Another fool that got F on his homework.

    Not one word about AIS deals with TEVA and injector business.

    So here is Tappy post from SA:

    I have a very large position in AIS; and any interest that I

    have in BioSante is only in how it affects Antares. That said:

    BioSante is, I believe, an excellent speculation because LibiGel

    should be a blockbuster drug, and every indications is that the

    soon to be released efficacy trial results will be fine, and

    in less than a year the safety trial results will follow, as will

    an NDA filing, approval, licensing and a very large pay day for

    both companies.

    While having domestic rights (and a few additional small markets)

    to a block-buster drug (assuming good and honest management,

    no large burn from other activities, etc.) is a printing press for

    money - I see LibiGel, as basically all BioSante has.

    AIS has an interest in LibiGel- which most people see as less

    than the LibiGel opportunity for BioSante.

    I see it differently:

    AIS receives 25% or up-front and milestone payments from a

    BioSante sub-licensing agreement. BioSante receives 75%--

    BUT BioSante is spending around $100 million to conduct clinical

    trials- AIS spends zero. When you net out BioSante's 75%

    minus $100 million- and compare that to AIS' undiminished 25%

    I think AIS might well have the advantage.

    AIS receives about 5% royalty on domestic product sales and

    BioSante will no doubt negotiate a larger percentage: but AIS

    has worldwide rights (excluding a few small markets) and a large

    royalty percentage on these potential global sales could easily

    equal that which BioSante will receive from domestic sales.

    SO IF BIOSANTE HAS AN BETTER OPPORTUNITY WITH

    LIBIGEL - IT IS PRETTY CLOSE.

    Then add all of AIS other benefits. Two launched products in both

    of their platforms (Elestrin Gel and Tev-Tropin injectable's); near

    profitability and a very small burn while we wait; Anturol waiting

    for FDA approval in early December (OAB gel drug already licensed

    by Watson Pharmaceutical); Two TEVA injectable's waiting for FDA

    approval; a potentially excellent contraceptive gel partnered with

    the Population Council and probably licensed to a drug company in

    2012; Two additional TEVA injectable's in clinical trials; and a

    transforming event which is AIS' development in a Methotrexate

    injectable (which is low risk and low cost- with a potentially high

    return) that will transform AIS from a company collecting

    (significant) royalty income - to a company developing and marketing

    their own products for a much larger slice of the pie. AIS has

    excellent institutional ownership and good analyst's coverage.

    In conclusion: I see AIS as an almost zero risk investment with the

    potential to double or triple in the very near term (moved along

    by the two catalysts of LibiGel trial results and Anturol approval-

    both coming before 2011 year end)- and with profitability in 2012,

    the chance for a double digit share price before this time next year.

    GOOD LUCK

  • Report this Comment On November 22, 2011, at 5:35 PM, noamps wrote:

    And another one from tappy, plus link to AIS presentation - at least i do my homework...

    # ANTARES (AIS) puts out an Investor Presentation most

    every month on their web site. They just issued on for

    September: Try this link--

    http://www.antarespharma.com/corporate/

    click on the September Report.

    Here is what they list as Potential Milestones for Next 12-18 Months

     Anturol approved, launched by Watson

     Teva Epinephrine project approved and launched

     2nd Teva auto-injection project approved and launched

     Other Teva programs advance including first Pen Program

    Filing (ANDA)

     LibiGel approved and launched

     Methotrexate NDA filed in US, Canada and Europe

     Methotrexate partnership in Europe

     Company cash flow positive

    HERE'S WHAT I THINK OF IT---

    If I (or I think most experienced investors) read the report

    without knowing the share price and were asked to guess what

    it is-- I am quite confident they would value AIS at least 3-4

    times today's price.

    What's holding it down- who knows ? But it won't be held

    in check for very long. These "potential" milestones will (I

    believe) all become realities- with more waiting in the wings.

    It should be an exciting Q-4 and 2012 should see AIS in

    double digits.

    Sep 19 07:21 PM | 1 Like Like |Report Abuse |Link to Comment

    #

    Using Celgene Option Income To Speculate On Biotech [View article]

    Todd

    We seem to have a growing mutual admiration society- and I suspect, like me, you enjoy self depreciating humor. I find those

    who enjoy joking about themselves, are very confident people.

    If I thought you were a "simpleton" we surely would not be having

    this dialogue. You are a smart professional and from all initial

    impressions a man of integrity.

    I post on the yahoo message board as: Tappy - others who are

    very credible: Jab; Rymankoly, Koufax and a few others.

    As for Leaders of Sovereign Nations who you sometimes don't believe- I think once we got past George Washington we went down hill, and our country is better than most.

    And "sorting out the lies and inaccuracies" told by management of pubic companies- one reason I like

    AIS is that they have integrity. They try to under promise and over-perform.

    Have a great weekend and let's hope for a good coming week.

    Tappy

  • Report this Comment On November 22, 2011, at 5:54 PM, noamps wrote:

    And another one from Tappy:

    AIS now has two drug delivery platforms:

    Advance Transdermal Gel and Injectable.

    We initially bought the stock for the Gels- but now- while the Gels

    hold excellent profit potential (see below) the Injectable's have

    overtaken the Gels as what will be the prime mover for AIS.

    All that AIS does requires FDA approvals- but combining existing,

    already approved drugs, with AIS delivery (and at this time AIS

    has FDA approvals in both of their platforms (Gels and Injectable's) -

    The bar for approvals is very low and any regulatory risk is small.

    The Transdermal Gel technology often provides a far better side

    effect profile than oral medication with equal or better efficacy.

    It can be thought of as the second generation of "The Patch" which

    is has multi billion dollar sales, but often (due to humidity and

    temperature, etc.) can deliver irregular doses (too much or too

    little) and can cause significant skin irritation. The gels eliminate

    these problems.

    Also it is important to note- that while anyone familiar with Gels

    recognized their medical benefit; but some may think is it a "messy"

    delivery. To the contrary- AIS' transdermal gel is not smeared

    on as sun-screen is used- rather it is a small dab (measured dose),

    usually applied to the shoulder, upper arm, abdomen, etc. from

    an applicator.

    It is almost instantly absorbed and leaves no residue on the skin.

    It can not be accidentally rubbed or washed off. I have heard it

    described as an "elegant delivery".

    AIS has 4 active Gel opportunities (and one on the shelf).

    1. Is LIBI-GEL which will be the first U.S. approved drug to treat

    Female Sexual Dysfunction (a patient population, at least, equal to

    that of men with ED; and such a drug is often referred to as: Pink

    Viagra).

    LibiGel should be a "blockbuster" drug (which commonly means

    annual sales of $1+ billion).

    AIS owns, and has licensed LibiGel, to BioSante Pharma for sales in

    N. America and a few very minor markets. BioSante has stated they

    intend to sub-license LibiGel in 2011 or early 2012. (AIS will

    receive 25% of all up-front and milestones and a 5.5% royalty on

    sales. BioSante receives 75% of up-front and milestones- but when

    you net out BioSante's 75% [after deducting the $90 million cost of

    clinical trials] - against AIS' 25% -- the up-front money to each

    company should be about equal). BioSante's domestic royalty will be

    more than AIS' 5.5% but when you add AIS' international opportunities,

    royalty income could be near equal).

    BioSante has little more than LibiGel, but as a pure play speculative

    stock, their market cap is about $100 million more than that of AIS

    (indicating AIS is being given no value for LibiGel - I think a very good

    case could be made that, based on the market cap of BioSante- AIS

    stock should [today] be $3 higher than it is-- based on LibiGel alone).

    AIS has retained the rights to the rest of the world. BioSante is spending

    an estimated $90 million to conduct clinical trials; and they have

    completed enrollment in the phase 3 trial, and expect an NDA submission

    to the FDA in very early 2012 and approval later that year. I am confident

    LibiGel will receive FDA approval for the following reasons.

    1. They are operating under an FDA "special assessment protocol"

    which effectively means the end points are previously agreed upon

    and, if the drug meets these end points, it will be approved so

    much of the subjectivity removed. 2. The FDA has publicly stated

    that Female Sexual Dysfunction is an "unmet medical need". 3. The

    FDA division which rules on approval is the "Urological and

    Reproductive Division" of the FDA and they have previously approved

    "Elestrin" (which is an AIS female hormone replacement gel drug

    licensed to BioSante). 4. Trial results to date have been excellent as

    to both safety and efficacy. 5. LibiGel is low dose testosterone and

    there are currently over 4 million "off label" prescriptions written

    each year in the U.S. for this use; and an approval drug would give

    the FDA control over a product for which they now have little control.

    6. A Low Dose testosterone gel product developed by P & G "Intrinsa"

    to treat women's sexual dysfunction is approved and selling in Europe

    with good results and no adverse effects.

    AIS retains all rights to LibiGel outside of BioSante's area and

    AIS has the right to use BioSante date for international approval;

    with no cost to AIS.

    I will get into the economics of LibiGel later in my earnings paragraph.

    2. ELESTRIN: is an "approved and launched" AIS female hormone

    replacement gel drug; used to replace the natural depletion of estrogen,

    lost as a woman ages. Symptoms of this problem range from

    manageable to uncontrollable "hot flashes" and a greatly diminished

    quality of life. The problem affects a great majority of mature women.

    Elestrin was licensed to BioSante (who in error sub-licensed it to

    Bradley Pharmaceuticals, who was in a takeover battle, and never

    launched the product).

    BioSante re-acquired rights from Bradley and sub-licensed to Azur

    Pharma who successfully launched the product.

    About a year ago Azur offered AIS and BioSante approximately

    $4+ million (each) as an advanced/discounted royalty payment to

    buy out future royalty payment obligations. BioSante took the offer

    as they were funding expensive LibiGel trials. AIS refused, as they

    wanted the recurring and growing income stream. This has worked

    out well for AIS.

    Female hormone replacement is associated; in rare instances,

    with heart attacks, strokes and blood clots. This is because oral

    hormones are metabolized in the liver, which also plays a part in

    the blood clotting process. Elestrin passes the liver and these risk

    factors are eliminated. Also hormone replacement has been associated

    with breast cancer and Elestrin was FDA approved as the "lowest

    effective dose" and the lower the dose the less chance for breast

    cancer. Elestrin has been a reasonably successful product, that has

    the capability to really catch fire and be an excellent revenue producer.

    3. ANTUROL is an AIS gel drug to treat overactive bladder, which affects

    a great majority of older people (mostly women); and is characterized

    by urgent, frequent, or uncontrolled urination; causing accidents and/or

    runs to the bathroom - which is highly inconvenient and embarrassing.

    The market for OAB drugs in the U.S. is around $3+ billion and

    Oxybutynin is the gold standard treatment for OAB; but orally

    it causes dry eye, dry mouth and constipation. Anturol is an

    Oxybutynin gel and, in this form, the above side effects are eliminated.

    Clinical trials have been completed and there is an FDA decision

    due (on or before) December 12th. Clinical trial results were

    excellent and I believe approval is almost assured.

    AIS expects to license this drug this year; and the up-front

    payments should be several million dollars; with continuing royalties

    on product sales in the mid to high teens and could run to 20+ %.

    4. NESTERGEL: AIS owns, and is working with The Population Council

    on this novel Gel contraceptive product which has distinct advantages

    over other forms of birth control. They are now in phase 2 clinical

    trials with excellent results to date. AIS has stated that the Population

    Council expects to license NesterGel (to a third party drug company)

    in the near to mid term. The market opportunity is extremely large,

    but I don't have a real handle on anticipated up-front money or

    licensing revenue. So NesterGel is not included in my revenue

    estimates.

    5. Ripioirole is an AIS product for restless leg syndrome. It was

    licensed to Jazz Pharmaceuticals but due to problems at Jazz it

    was put on hold, where it remains.

    In order to concentrate on a greater opportunity in the Injectable

    side of their business, and to reduce a significant cash drain- AIS

    sold future gel development to their European partner - Ferring

    for a few million dollars and (perhaps) future milestone payments.

    AIS received a $1/2 million milestone about a year ago from Ferring

    in this matter. AIS retains all the benefits of their existing gel

    drugs (above) and has all rights in Europe, S. America and Asia;

    which are now uncommitted, and AIS expect will make a reasonable

    contribution to future earnings, but is not figured into my financial

    projections.

    Injectable Division:

    In this area AIS' products are compatible with drugs in the Bio-

    Equivalent and Bio-Better market which is dominated by generic drug

    companies and is current at $25 billion; slated to grow to $125 billion

    by 2015. TEVA is the dominant player in this field as the largest

    generic drug company in the world; and TEVA has four licensing deals

    with AIS covering five products.

    The first TEVA/ AIS licensing agreement is for HUMAN GROWTH

    HORMONE and the product is named Tev-Tropin. It is fully FDA "approved

    and launched". Teva recently paid AIS a $1/2 million milestone payment

    for Tev-Tropin meeting (or exceeding) sales projections.

    The second and third TEVA/ AIS product is for (2) Epinephrine for

    Anaphylaxis which is a severe systemic allergic reaction resulting from

    exposure to allergens that is rapid in onset and can cause death. The

    (3rd) is for a yet undisclosed product (widely thought to be Sumatriptan

    for treatment of migraine). Both products have NDA's pending before

    the FDA and approval and launch is expected this year.

    (note: TEVA/AIS epinephrine is currently in litigation for patent

    infringement claimed by King Pharmaceuticals. All of my sources advise

    the TEVA is the clear winner and to expect a settlement. If not

    TEVA should launch "at risk" and there should be no negative impact to

    AIS).

    TEVA/ AIS 4 and 5 are in mid stage clinical trials. The products

    have not been identified; but it has been publicly disclosed that the

    combined markets for these two products is $1.6 Billion and the

    Royalty percentage to be paid by TEVA to AIS in in the mid teens.

    This is not included in my revenue estimate; as it is some years away:

    (However to look at the projected numbers: TEVA targets. and almost

    always captures. at least 10% of a market. With a $1.6 Billion market;

    TEVA should develop sales of $160 million and a royalty revenue

    stream to AIS (at the low end of announced revenue percentages of

    15%) -- that would mean annual income to AIS of $24 million).

    Recent reassurance of the strength of the TEVA/ AIS relationship

    was receipt about 18 months ago of a $4 million payment from TEVA

    to AIS which was earmarked for "future product development". The

    $1/2 million milestone payment (mentioned above) for the success of

    Tev-Tropin. Dr. Leonard Jacob Chairman of the Board of AIS) and

    Wm. Marth (CEO of TEVA) were recently appointed to the board of

    the Institute for Scientific Research in Philadelphia. And in the last

    quarterly conference call Dr. Wotton (CEO of AIS) described the

    TEVA relationship as "Phenomenal" - which is of particular note; as

    Dr. Wotton is very understated.

    THIS IS HOW I EXPECT AIS TO REACH SALES OF $100 MILLION:

    (AND THIS IS ROYALTY INCOME WITH NO COST OF GOODS SOLD

    SO EXCEPT FOR SG & A - AND- R & D MOST OF THIS REVENUE

    WILL COME TO THE BOTTOM LINE) AND THIS INCOME IS BOTH

    RECURRING AND GROWING:

    How do we get to earn $100 million.

    1. LibiGel should easily be a $1 billion "blockbuster" drug-

    and our royalty is 5.5% or $55 million a year of recurring and

    growing income to AIS. That is on domestic sales: AIS owns all

    international rights to LibiGel and it is currently uncommitted.

    2. Anturol should be licensed this year for several million dollars

    up-front and a royalty of probably mid teens- On Anturol sales

    of $60 million AIS' royalty income would be nearly $10 million

    (and Anturol could easily produce $100 million in sales and generate

    $15+ Million to AIS). OAB is a multi-billion $ market and Anturol

    has one of the best side effect profiles of any existing drug.

    3. Elestrin should earn AIS $3 -5+ million a year.

    4. Tev-Tropin (first launched AIS/TEVA product) HGH is a $1.3

    Billion market - TEVA should easily capture 10%+ of the market

    or sales of $100+ million. AIS' royalty plus device sales should

    average 10%, or $10 million a year to AIS.

    5. TEVA/AIS Epinephrine: the market is $250 million - TEVA should

    capture 20% and AIS receives an 8% royalty or $4 million a year.

    6. TEVA/AIS # 3 product is undisclosed but thought to be Sumatriptan:

    Similar opportunity for AIS as with Epinephrine - $4 million a year to

    AIS.

    7. Current revenue for AIS - mostly from Ferring sales in Europe

    around $14 million a year

    THE ABOVE TOTAL $101 MILLION IN ROYALTY INCOME

    TO AIS: With 100 million shares outstanding this is (more

    of less) income of $1 a share..

    It does not take into consideration:

    1. TEVA 4 & 5 (which will sell into a $1.6 billion market - TEVA targets

    and traditionally captures at least 10% of any market they enter for

    sales of $160 million and AIS will receive a mid teens royalty (say 15%)

    for income of $24 million).

    2. Any monetizing of AIS' gel opportunities outside of N. America.

    3. Any up-front and milestone payments from licensing of LibiGel;

    Anturol and NesterGel which could easily be in the tens of millions of

    dollars.

    4. The very significant opportunity with Methotrexate.

    5. And any new licensing deals which I think are inevitable: and at

    least one new deal is projected this year by the Ladenburg-Thalmann

    analyst, Matthew Kaplan; who I think is the smartest, small Pharma

    analyst on Wall Street.

    AIS formerly had little, or no, Investor or Public Relations, as

    they felt the story was not ready to be told. Several months ago they

    engaged Westwicke Partners to represent AIS with IR/PR (mostly

    in dealing with institutional clients). They are first rate and I suggest

    you visit the Westwicke web site to see their qualifications.

    For me to write here about some of the technical aspects of the

    Injectable platform and/or to discuss financial's would be to merely

    parrot information that is readily available on the AIS web site:

    www.antarespharma.com . Plus as a company now successfully

    transitioning from an R & D company (not expected to generate much

    revenue and lose money): To one which is successfully commercializing

    their products - historical revenue data is of little use.

    The AIS web site, while not spectacular, contains good information.

    If you are interested, and if they are still archived, I suggest you

    listen to the most recent quarterly conference call and any web-

    casts from institutional health care conferences. Also, to learn

    more about LibiGel you might want to visit the BioSante web site

    and bring up any presentations made by them recently.

    Again, thanks for your interest and I wish you good luck if you decide

    to build a position in AIS stock.

  • Report this Comment On November 22, 2011, at 6:00 PM, erikshun wrote:

    re: yazzbro

    yes, i am being conservative in my guesstimate. i am pushing for double digits as well, but one can never predict a future stock price so i err on the side of conservatism here. i would not be surprised to see it double or even triple Q1 '11, but we gotta hit $4 first!

  • Report this Comment On November 23, 2011, at 11:24 AM, yazzbro wrote:

    Haha, I love guys who quote Tappy. He is the biggest Pump and Dump guy ever. He has been pumping AIS for a long time now. And if you read his stuff it is nothing but pure speculation bording on the realm of grandeur. A lot of "if's" have to happen in order for Tappy's numbers to jive. The point is, is that AIS is a speculative play no matter how you look at it. Yes, it has some products on the market right now but, not enough to really push AIS over the top. The really money will be in the results of Libigel,(Which nobody can say for sure what they will be until the results are posted) and Anturol(which we don't know what the FDA will say.) I love guys who try to down play the importance of Anturol. If Anturol doesn't get FDA approval this will send investors to the exits and right quick. The reason being is that it will take more money to conduct further trials to get Anturol a second shot at the FDA. Biopharm Investors are an impatient bunch. They play the hype. They rarely keep these stocks as a super long term play. They are in and out. So if the results are good, they cash out. If the results are bad they are gone and on to the next biopharm stock. So to be told that even if Anturol is reject that Antares will still be a good stock, is really wishful thinking. The best scenario to play out is that Libigel topline results come out "BEFORE" any news on Anturol. Getting good topline results for Libigel will send this stock up toward $5 and then you can place hard stops on AIS and await the Anturol results. If Anturol comes out first and the results aren't good then this is not going to be pretty because, now you are holding the ball until Libigel results are published and then you better hope they are good to at least get your money back. So hold on to your hats, December can prove to be a wild ride for investors of AIS.

  • Report this Comment On November 23, 2011, at 5:20 PM, techperson wrote:

    Female sexual dysfunction, or Hypoactive Sexual Desire Disorder (HSDD), affects millions of women in the U.S., especially those past menopause. It is more common than erectile dysfunction, which is a $2 billion per year prescription business in the U.S. There currently are no FDA approved drug therapies for the treatment of HSDD in women.

    Projections for the U.S. market alone range from $2.0 billion to $5 billion in sales. Not only does Antares get a royalty on that, but they own the rest-of-world rights.

Add your comment.

DocumentId: 1593940, ~/Articles/ArticleHandler.aspx, 4/19/2014 8:55:27 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement